IPHASE DS8201a

Short Description:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Product Detail

Product Tags

  • Product discription DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.
    • Category:
      Cathepsin
    • Item NO.:
      015200.01
    • Unit Size:
      50uL,2mg/mL
    • Tissue:
      N/A
    • Species:
      N/A
    • Storage conditions and transportation:
      Store at -70°C. Dry ice delivered.

  • Previous:
  • Next:
  • Language Selection